Amarin’s moment of truth

Shares of the biotech company Amarin are up almost tenfold since September, when the company said that its modest-selling cardiovascular drug led to major long-term improvements in patient health.

But that was based on a few figures in a press release. This weekend, we’ll find out all the gritty details, which will determine whether Amarin’s pill is really a major advance in cardiovascular care or whether there’s a sizable asterisk lurking somewhere in the data.

On Saturday, the company will present the full results of its study at the American Heart Association’s annual gathering in Chicago. If the results hold up, one of the year’s most surprising stories in biotech will only get better. If not, Amarin’s $6.6 billion market cap might not make it through Monday.

Stay tuned to STAT for the news once it happens.